Your browser doesn't support javascript.
loading
Diaphragmatic and intercostal electromyographic activity during neostigmine, sugammadex and neostigmine-sugammadex-enhanced recovery after neuromuscular blockade: A randomised controlled volunteer study.
Cammu, Guy; Schepens, Tom; De Neve, Nikolaas; Wildemeersch, Davina; Foubert, Luc; Jorens, Philippe G.
Afiliação
  • Cammu G; From the Department of Anaesthesiology and Critical Care Medicine, Onze-Lieve-Vrouw Ziekenhuis, Aalst (GC, NDN, LF); Department of Anaesthesiology, (TS, DW); Department of Critical Care Medicine, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium (PGJ).
Eur J Anaesthesiol ; 34(1): 8-15, 2017 01.
Article em En | MEDLINE | ID: mdl-27902641
ABSTRACT

BACKGROUND:

Electromyographic activity of the diaphragm (EMGdi) during weaning from mechanical ventilation is increased after sugammadex compared with neostigmine.

OBJECTIVE:

To determine the effect of neostigmine on EMGdi and surface EMG (sEMG) of the intercostal muscles during antagonism of rocuronium block with neostigmine, sugammadex and neostigmine followed by sugammadex.

DESIGN:

Randomised, controlled, double-blind study.

SETTING:

Intensive care research unit.

PARTICIPANTS:

Eighteen male volunteers.

INTERVENTIONS:

A transoesophageal EMGdi recorder was inserted into three groups of six anaesthetised study participants, and sEMG was recorded on their intercostal muscles. To reverse rocuronium, volunteers received 50 µg kg neostigmine, 2 mg kg sugammadex or 50 µg kg neostigmine, followed 3 min later by 2 mg kg sugammadex. MAIN OUTCOME

MEASURES:

We examined the EMGdi and sEMG at the intercostal muscles during recovery enhanced by neostigmine or sugammadex or neostigmine-sugammadex as primary outcomes. Secondary objectives were the tidal volume, PaO2 recorded between the onset of spontaneous breathing and extubation of the trachea and SpO2 during and after anaesthesia.

RESULTS:

During weaning, median peak EMGdi was 0.76 (95% confidence interval 1.20 to 1.80) µV in the neostigmine group, 1.00 (1.23 to 1.82) µV in the sugammadex group and 0.70 (0.91 to 1.21) µV in the neostigmine-sugammadex group (P < 0.0001 with EMGdi increased after sugammadex vs. neostigmine and neostigmine-sugammadex). The median peak intercostal sEMG for the neostigmine group was 0.39 (0.65 to 0.93) µV vs. 0.77 (1.15 to 1.51) µV in the sugammadex group and 0.82 (1.28 to 2.38) µV in the neostigmine-sugammadex group (P < 0.0001 with sEMG higher after sugammadex and after neostigmine-sugammadex vs. neostigmine).

CONCLUSION:

EMGdi and sEMG on the intercostal muscles were increased after sugammadex alone compared with neostigmine. Adding sugammadex after neostigmine reduced the EMGdi compared with sugammadex alone. Unlike the diaphragm, intercostal EMG was preserved with neostigmine followed by sugammadex. TRIAL REGISTRATION EudraCT 2015-001278-16; ClinicalTrials.gov NCT02403063.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Diafragma / Músculos Intercostais / Inibidores da Colinesterase / Fármacos Neuromusculares não Despolarizantes / Bloqueio Neuromuscular Tipo de estudo: Clinical_trials Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Diafragma / Músculos Intercostais / Inibidores da Colinesterase / Fármacos Neuromusculares não Despolarizantes / Bloqueio Neuromuscular Tipo de estudo: Clinical_trials Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article